Back to Newsroom

Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections

SAN DIEGO, Jan. 18, 2018 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 (“the ‘418 Application”), entitled “METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS.” The allowed claims of the ‘418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients.